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We developed a system for rapid determination of
viral RNA sequences whereby genomic sequence is
obtained from cultured virus isolates without subcloning
into plasmid vectors. This method affords new opportuni-
ties to address the challenges of unknown or untypeable
emerging viruses.
O
ver the past few years, global migration has led to
emerging infectious diseases that pose substantial
risks to public health. To prevent potential outbreaks, early
detection of infectious pathogens is necessary. In particu-
lar, the recent outbreak of severe acute respiratory syn-
drome (SARS) provided important lessons on how
unknown viruses should be detected rapidly. Thus, a stan-
dardized and qualified system is required for rapid nucleic
acid sequence determination for newly emerging viruses.
Recently, we developed a new method for detecting
RNA viruses. This method, based on cDNA representa-
tional difference analysis (cDNA RDA), uses 96 hexanu-
cleotides that are not suitable for priming ribosomal RNAs
but that normally prime most of the genome of an RNA
virus as primers for reverse transcription in cDNA RDA
(1). However, the RDA method with a cloning step
requires at least 1 week for the determination of the nucle-
ic acid sequence.
The Method
Our new system for rapid determination of viral RNA
sequence (RDV) uses whole-genome amplification and
direct sequencing techniques (Figure 1). The RDV method
comprises 6 procedures: 1) effective destruction of cellular
RNA and DNA for semipurification of viral particles, 2)
effective elimination of DNA fragments by using a pre-
filtration column system and elution of small amounts of
RNA, 3) effective synthesis of first- and second-strand
cDNAs, 4) construction and amplification of a cDNA
library, 5) construction of a second cDNA library, and 6)
direct sequencing using optimized primers. The RDV
method enables a broad range of partial nucleotide
sequences within the entire viral RNA genome to be
obtained within 2 days without cloning into plasmids.
To eliminate contaminating cellular RNA and DNA
from the samples, 0.001 µg of RNase A (Qiagen, Hilden,
Germany) and 1 µL (2 U) of Turbo DNA-free DNase I
(Ambion, Austin, TX, USA) with 1× Turbo DNA-free
buffer were incubated at 37°C for 30 min under conditions
that prevented destruction of viral RNA in the viral parti-
cles. The RNA in the viral particles was then extracted
within 30 min by using a total RNA isolation mini kit
(Agilent Technologies Inc., Palo Alto, CA, USA). We con-
firmed that DNA was effectively eliminated by this RNA
extraction kit.
In accordance with the Invitrogen manual, cDNA was
synthesized, by using random hexamers (Takara Bio Inc.,
Kyoto, Japan) and Superscript III (Invitrogen, Carlsbad,
CA, USA) lacking RNase H activity, at 50°C for 1 h. Then
60 U of RNase H (Takara Bio Inc.) added before synthesis
of second-strand cDNAat 50°C for 1 h. In accordance with
the manual, a whole genome amplification system (WGA;
Sigma-Aldrich, Saint Louis, MO, USA), which was devel-
oped for amplification of genomic DNA, was used to
amplify viral double-stranded cDNA. This process was
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Figure 1. Overall scheme of the rapid determination of viral RNA
sequence method. *By adding RNase H; WGA, whole genome
amplification; †With specially designed primer sets as shown in
Figure 2.performed within 90 min. Instead of the Taq polymerase
recommended in the kit, we used 1.25 U of AmpliTaq Gold
LD (Applied Biosystems, Foster City, CA, USA) to obtain
a high yield of the PCR products. Primers were provided
in the WGA kit, but no information regarding their
sequences was obtained. The reaction mixture was heated
at 95°C for 9 min (for activation of AmpliTaq Gold), fol-
lowed by 70 cycles of amplification using Mastercycler
(Eppendorf AG, Hamburg, Germany). Each PCR cycle
consisted of annealing at 68°C for 1 min, primer extension
at 72°C for 5 min, and denaturation at 94°C for 1 min.
The 1st cDNA library was digested with 40 U of
HaeIII (Takara Bio Inc.) at 37°C for 30 min. DNA was
purified by using the MonoFas DNA isolation system (GL
Science, Tokyo, Japan), and a blunt EcoRI-NotI-BamHI
adaptor (10 pmol; Takara Bio Inc.) was ligated at 16°C for
30 min by using DNA Ligation Kit, Mighty Mix (Takara
Bio Inc.). The second cDNAlibrary was amplified by PCR
with specially designed primer sets in which 6 nucleotides
composed of CC (HaeIII-digested sequence) and 4 vari-
able nucleotides were added to the 3′ end of the adaptor
sequence (Figure 2). For example, 1 primer set was as fol-
lows: forward primer, H1–1: 5′-AATTCGGCGGCCGCG
GATCCCCGGGG-3′; reverse primer H9–3: 5′-AATT
CGGCGGCCGCGGATCCCCAGGA-3′ (the adaptor
sequence is underlined, and the HaeIII-digested sequence
is shown in italics) (Figure 2).
We always used >12 primer sets and 0.83 µmol of
each primer per cDNA library. PCR was performed with
AmpliTaq Gold Master Mix (Applied Biosystems). The
reaction mixture was heated at 95°C for 12 min, followed
by 70 cycles of amplification. Each PCR cycle consisted of
annealing and primer extension at 72°C for 30 s and denat-
uration at 94°C for 30 s. A single band was consistently
obtained in ≈50% of the reactions. DNAwas purified from
the PCR by using MonoFas. Occasionally, we purified
DNA fragments from the gels when >2 bands were detect-
ed. Direct sequencing was performed with the forward
primer, reverse primer, or both.
When the number of viral particles in the sample was
high, we omitted the RNase A and DNase I treatments and
used the RNeasy Mini Kit (Qiagen) for RNA extraction.
We occasionally used a whole transcriptome amplification
kit (Rubicon Genomics Inc, Ann Arbor, MI, USA) instead
of the WGA kit because both kits yielded similar amplifi-
cation results.
In preliminary studies that used referential RNAvirus-
es, we attempted to determine the nucleic acid sequences
of SARS coronavirus, mouse hepatitis virus, West Nile
virus, Japanese encephalitis virus, and dengue virus type 2
in culture supernatants (10–100 µL) by using the RDV
method. The percentages of positive fragments (number of
fragments containing viral nucleic acid/total number of
sequenced fragments) in the reactions for detection of
these 5 viruses were 60% (3/5), 45% (5/11), 100% (12/12),
50% (5/10), and 40% (4/10), respectively. As a clinical
application, a throat swab specimen from a patient with
fever and upper respiratory infection was characterized.
Although the specimen exhibited enterovirus-like cyto-
pathic effect by inoculation into HEF and GMK cells when
cell culture system for virus isolation was used (2), extract-
ed RNA from the supernatant of the cells showed no
amplification by reverse transcription–PCR (RT-PCR)
when 1 of the conventional primer sets for human
enteroviruses was used (3,4). In the cell culture super-
natant analysis by the RDV method, the specimen exhibit-
ed amplification of the partial nucleotide sequences of
coxsackie A14 virus (nucleotide sequence data are avail-
able in the DDBJ/EMBL/GenBank databases under acces-
sion nos. AB275848–AB275853). Thus, the RDV method
could detect unidentified cytopathic-effect agents such as
enterovirus that could not be detected by RT-PCR when
the conventional primer set for enteroviruses was used.
Conclusions
The RDV method is a rapid method for the direct
determination of viral RNA sequences without using the
cDNA cloning procedure. The limitations of the RDV
method are the requirement for cell culture isolate and the
large number of steps. However, RDV would be useful for
species-independent detection of RNA viruses including
unknown or untypeable emerging RNA viruses.
Furthermore, with minor modifications, this method
would also be applicable to the detection of DNA viruses
and bacteria. 
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Figure 2. Primers used in rapid determination of viral RNA
sequence method.Acknowledgments
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